Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Annals of Oncology

Volumn 27, Issue 7, 2016, Pages 1336-1341

  Chung, J H ^a   Sanford, E ^a,f   Johnson, A ^a   Klempner, S J ^b   Schrock, A B ^a   Palma, N A ^a   Erlich, R L ^a   Frampton, G M ^a   Chalmers, Z R ^a   Vergilio, J ^a   Rubinson, D A ^c   Sun, J X ^a   Chmielecki, J ^a   Yelensky, R ^a   Suh, J H ^a   Lipson, D ^a   George, T J ^d   Elvin, J A ^a   Stephens, P J ^a   Miller, V A ^a   Ross, J S ^a,e   Ali, S M ^a   more..

^a FOUNDATION MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anal squamous cell carcinoma; Comprehensive genomic profiling; HPV; PI3KCA; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; NUCLEAR PROTEIN; PI3KCA PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; AKT GENE; AKT1 GENE; AKT3 GENE; ANAL SQUAMOUS CELL CARCINOMA; ANUS CARCINOMA; ARTICLE; CANCER GRADING; CDKN2A GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COPY NUMBER VARIATION; DNA REPAIR; DNA SEQUENCE; EXON; FBXW7 GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE REARRANGEMENT; GENETIC ALGORITHM; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INTRON; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MTOR GENE; NEXT GENERATION SEQUENCING; ONCOGENE MYC; PAPILLOMAVIRUS INFECTION; PI3K GENE; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RICTOR GENE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STK11 GENE; TP53 GENE; VIRUS GENOME; ANUS TUMOR; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P18; EXONS; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84977155406     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw152     Document Type: Article

References (31)

1. Shiels MS, Kreimer AR, Coghill AE et al. Anal Cancer Incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev 2015; 24: 1548-1556.
2. Benson AB, Arnoletti JP, Bekaii-Saab T et al. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10(4): 449-454.
3. Bernardi M-P, Ngan SY, Michael M et al. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol 2015; 16(16): e611-e621.
4. Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365(17): 1576-1585.
5. Holman DM, Benard V, Roland KB et al. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014; 168(1): 76-82.
6. James RD, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, × 2 factorial trial. Lancet Oncol 2013; 14(6): 516-524.
7. Eng C, Chang GJ, You YN et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014; 5(22): 11133-11142.
8. Smaglo BG, Tesfaye A, Halfdanarson TR et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015; 6 (41): 43594-43604.
9. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153(1): 17-37.
10. Lawrence MS, Sougnez C, Lichtenstein L et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517 (7536): 576-582.
11. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31(11): 1023-1031.
12. Lechner M, Frampton GM, Fenton T et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV + and HPV- tumors. Genome Med 2013; 5(5): 49.
13. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304(5670): 554.
14. Casadei Gardini A, Capelli L, Ulivi P et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One 2014; 9(3): e92071.
15. Paliga A, Onerheim R, Gologan A et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 2012; 107(11): 1864-1868.
16. Meulendijks D, Tomasoa NB, Dewit L et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer 2015; 112(8): 1358-1366.
17. Chung CH, Guthrie VB, Masica DL et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 2015; 26(6): 1216-1223.
18. Wang K, Johnson A, Ali SM et al. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist 2015; 20(10): 1132-1139.
19. Ojesina AI, Lichtenstein L, Freeman SS et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506(7488): 371-375.
20. Elvin JA, Bailey M, Carneiro BA et al. Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identify targeted therapy options. J Clin Oncol 2015; 33(suppl): abstr 5602.
21. Ali SM, Pal SK, Wang K et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncologist 2015; 21(1): 33-39.
22. Fritsch C, Huang A, Chatenay-Rivauday C et al. Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014; 13(5): 1117-1129.
23. Soria J-C, DeBraud F, Bahleda R et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014; 25(11): 2244-2251.
24. Bass AJ, Watanabe H, Mermel CH et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41(11): 1238-1242.
25. Wang C-Y, Filippakopoulos P. Beating the odds: BETs in disease. Trends Biochem Sci 2015; 40(8): 468-479.
26. Seiwert TY, Zuo Z, Keck MK et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015; 21(3): 632-641.
27. Morris VK, Rashid A, Rodriguez-Bigas M et al. Clinicopathologic features associated with human papillomavirus/p16 in patients with metastatic squamous cell carcinoma of the anal canal. Oncologist 2015; 20(11): 1247-1252.
28. Martin V, Zanellato E, Franzetti-Pellanda A et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol 2014; 29(4): 513-521.
29. Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006; 19(7): 942-949.
30. Lupini L, Bassi C, Mlcochova J et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer 2015; 15: 808.
31. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28(7): 1254-1261.